Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00028925 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy With or Without Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer
A Phase 2 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT00028925 is a Phase 2 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 27 participants.
The verdict
NCT00028925, a Phase 2 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to compare the effectiveness of combination chemotherapy with or without filgrastim in treating patients who have extensive-stage small cell lung cancer that has not been previously treated.
Interventions
- DRUG carboplatin
- BIOLOGICAL filgrastim
- DRUG topotecan hydrochloride
- RADIATION WBRT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2001-11 |
| Est. Completion | 2008-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00028925
The ClinicalTrials.gov registry entry for NCT00028925 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which carboplatin is the first listed.
NCT00028925 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00028925 about?
NCT00028925 is a clinical study titled "Combination Chemotherapy With or Without Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from th...
What is the current status of trial NCT00028925?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2001-11. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00028925?
The interventions under investigation include: carboplatin (DRUG), filgrastim (BIOLOGICAL), topotecan hydrochloride (DRUG), WBRT (RADIATION).
Who is sponsoring clinical trial NCT00028925?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.